Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKPancreas: Neoadjuvant Therapy for Pancreatic Cancer
NCT03199144Phase 2Withdrawn
- Sponsor
- Centre François Baclesse
- Start
- Apr 2017
- Primary completion
- Mar 2021
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nab-paclitaxel, gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Centre François Baclesse. Planned start Apr 2017; status: withdrawn.
02
Drugs
nab-paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03199144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03199144.